A study to find the effectivity of single injection of the drug Razumab in improving vision in the affected eye .This study will help the patients with diabetic eye problems by improving their vision and reducing the number of hospital visits.

Not Applicable

• Conditions: Health Condition 1: H00-H59- Diseases of the eye and adnexa

• Registration Number: CTRI/2022/05/042804
• Lead Sponsor: ESIC postgraduate institute of medical science and research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 May 2023

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

patients with diabetic macular edema or macular edema due to retinal vaso-occlussive disease with central macular thickness of less or equal to 315 micron and visual acuity of less or equal to 0.2 on LogMAR chart will be included in the study.

Exclusion Criteria

1. pre existing macular scar or dystrophy.

2.patients with active inflammatory and infectious diseases of the eye.

3. Patients already under treatment for macular edema in other hospital.

4.patients with history of recent ocular history or trauma.

5. patients with history of cerebrovascular or cardiovascular comorbidities.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1.the percentage of reduction of macular edema after 4 weeks. <br/ ><br>Timepoint: 1.the percentage of reduction of macular edema after 4 weeks. <br/ ><br>

Secondary Outcome Measures

Name	Time	Method
improvement in best corrected visual acuity after 4 weeks of injection of intravitreal RazumabTimepoint: 1.visual acuity and macular edema will be measured before the intravitreal antivegf injection. <br/ ><br>2. 1 week later, intraocular pressure is measured to rule out side effects. <br/ ><br>3. 1 month after the injection, visual acuity and macular edema will be re- assessed.